JOHN D. ARCHBOLD MEMORIAL HOSPITAL
- Type
- Teaching hospital
- Where
- Thomasville, GA
- Medicare CCN
- 110038
- Received
- $755,051 in 30 records, 2025 ($94,823 general, $660,228 research)
- Source
- CMS Open Payments search ↗
On this site
- Federal award recipient: JOHN D. ARCHBOLD MEMORIAL HOSPITAL, INC Fuzzy (name and state)
- Federal award recipient: JOHN D. ARCHBOLD MEMORIAL HOSPITAL, INC. Fuzzy (name and state)
- Nonprofit: JOHN D ARCHBOLD MEMORIAL HOSPITAL INC Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 9 | $94,823 |
| 2025 | Research payment | 21 | $660,228 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 3 | $301,642 | 2025 |
| Novartis Pharmaceuticals Corporation | 2 | $216,726 | 2025 |
| CathWorks, Inc. | 8 | $114,013 | 2025 |
| AngioDynamics, Inc. | 3 | $75,666 | 2025 |
| AstraZeneca UK Limited | 1 | $19,678 | 2025 |
| Stryker Corporation | 4 | $16,037 | 2025 |
| E.R. Squibb & Sons, L.L.C. | 2 | $6,083 | 2025 |
| Becton, Dickinson and Company | 2 | $3,119 | 2025 |
| Genentech, Inc. | 4 | $1,874 | 2025 |
| Regeneron Pharmaceuticals, Inc. | 1 | $209 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 21 | $660,228 |
| Long term medical supply or device loan | 9 | $94,823 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $134,442 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $100,617 | Research payment | In-kind items and services | Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatm | 2025 |
| 2025-12-31 | AngioDynamics, Inc. | $32,666 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2025 | |
| 2025-12-31 | AngioDynamics, Inc. | $30,000 | Long term medical supply or device loan | In-kind items and services | Auryon Laser System 100-120 Vac Device, CV | 2025 | |
| 2025-12-31 | AngioDynamics, Inc. | $13,000 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2025 | |
| 2025-12-31 | Stryker Corporation | $5,360 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $5,360 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $5,281 | Long term medical supply or device loan | In-kind items and services | Power PRO Device, EMS | 2025 | |
| 2025-12-31 | Stryker Corporation | $35 | Long term medical supply or device loan | In-kind items and services | Precision S 4K Device, ENDOSCOPY | 2025 | |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $209 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY | 2025 |
| 2025-11-12 | Genentech, Inc. | $90 | Research payment | Cash or cash equivalent | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | 2025 | |
| 2025-11-11 | Novartis Pharmaceuticals Corporation | $1,248 | Research payment | Cash or cash equivalent | A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment | 2025 | |
| 2025-10-17 | CathWorks, Inc. | $6,670 | Research payment | Cash or cash equivalent | FFRangio Device, CARDIOLOGY | ALL-RISE | 2025 |
| 2025-10-17 | CathWorks, Inc. | $2,000 | Research payment | Cash or cash equivalent | FFRangio Device, CARDIOLOGY | ALL-RISE | 2025 |
| 2025-08-31 | Merck Sharp & Dohme LLC | $66,582 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pemb | 2025 |
| 2025-06-22 | Becton, Dickinson and Company | $2,732 | Long term medical supply or device loan | In-kind items and services | HemoSphere Vita Device, Hemodynamic Monitoring | 2025 | |
| 2025-05-28 | CathWorks, Inc. | $1,650 | Research payment | Cash or cash equivalent | FFRangio Device, CARDIOLOGY | ALL-RISE | 2025 |
| 2025-05-28 | CathWorks, Inc. | $1,474 | Research payment | Cash or cash equivalent | FFRangio Device, CARDIOLOGY | ALL-RISE | 2025 |
| 2025-05-01 | Genentech, Inc. | $90 | Research payment | Cash or cash equivalent | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | 2025 | |
| 2025-04-17 | E.R. Squibb & Sons, L.L.C. | $1,875 | Research payment | Cash or cash equivalent | Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural hist | 2025 | |
| 2025-04-02 | AstraZeneca UK Limited | $19,678 | Research payment | Cash or cash equivalent | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next G | 2025 | |
| 2025-03-25 | CathWorks, Inc. | $25,894 | Research payment | Cash or cash equivalent | FFRangio Device, CARDIOLOGY | ALL-RISE | 2025 |
| 2025-03-25 | CathWorks, Inc. | $1,150 | Research payment | Cash or cash equivalent | FFRangio Device, CARDIOLOGY | ALL-RISE | 2025 |
| 2025-03-03 | E.R. Squibb & Sons, L.L.C. | $4,208 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, ve | 2025 |
| 2025-02-10 | CathWorks, Inc. | $72,525 | Research payment | Cash or cash equivalent | FFRangio Device, CARDIOLOGY | ALL-RISE | 2025 |
| 2025-02-10 | CathWorks, Inc. | $2,650 | Research payment | Cash or cash equivalent | FFRangio Device, CARDIOLOGY | ALL-RISE | 2025 |
| 2025-02-05 | Novartis Pharmaceuticals Corporation | $215,477 | Research payment | Cash or cash equivalent | KISQALI Drug, Oncology | A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment | 2025 |
| 2025-01-14 | Genentech, Inc. | $1,452 | Research payment | Cash or cash equivalent | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | 2025 | |
| 2025-01-14 | Genentech, Inc. | $240 | Research payment | Cash or cash equivalent | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | 2025 | |
| 2025-01-01 | Becton, Dickinson and Company | $387 | Long term medical supply or device loan | In-kind items and services | HemoSphere Vita Device, Hemodynamic Monitoring | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Thomasville, GA, county Thomas County, GA, state Georgia; placed by its city name.
| Measure | Place (city or town) Thomasville, GA | County Thomas County, GA | State Georgia |
|---|---|---|---|
| Population B01003 | 18,666 | 45,777 | 10,940,407 |
| Population, 2020 census P1 | 18,881 | 45,798 | 10,711,908 |
| Median age B01002 | 38.6 | 39.8 | 37.6 |
| Under 18 B01001 | 22.8% | 23.6% | 23.2% |
| 65 and over B01001 | 20.6% | 19.0% | 15.0% |
| Households B11001 | 7,929 | 18,684 | 4,074,366 |
| Foreign born B05002 | 2.7% | 2.7% | 11.2% |
| Median household income B19013 | $49,673 | $60,736 | $77,353 |
| Median family income B19113 | $77,459 | $85,125 | $93,754 |
| Per capita income B19301 | $35,327 | $33,700 | $40,924 |
| Poverty rate B17001 | 17.1% | 17.9% | 13.4% |
| Unemployment rate B23025 | 5.9% | 5.6% | 5.1% |
| Civilian labor force B23025 | 9,223 | 22,501 | 5,496,061 |
| Mean commute (minutes) B08013 | 16.3 | 20.1 | 28.3 |
| Bachelor's degree or higher B15003 | 24.9% | 22.7% | 34.9% |
| Housing units B25001 | 8,965 | 21,130 | 4,541,835 |
| Owner-occupied B25003 | 50.3% | 63.8% | 65.7% |
| Renters B25003 | 49.7% | 36.2% | 34.3% |
| Median home value B25077 | $205,200 | $196,700 | $303,300 |
| Median gross rent B25064 | $1,077 | $1,018 | $1,393 |
| White, not Hispanic B03002 | 39.6% | 57.0% | 49.1% |
| Black B03002 | 53.5% | 34.9% | 30.7% |
| Hispanic or Latino B03002 | 2.1% | 3.9% | 11.0% |
| Asian B03002 | 0.6% | 0.9% | 4.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.1% |
Economy now FRED unemployment 3.3% in Sep 2026 (3.4% a year earlier); per capita personal income $65,111 in 2025, up 26% in five years (+1.6% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Thomasville, GA.
Comments